1
|
Zhou S, Zhao W, Hu J, Mao C, Zhou M. Application of Nanotechnology in Thrombus Therapy. Adv Healthc Mater 2023; 12:e2202578. [PMID: 36507827 DOI: 10.1002/adhm.202202578] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2022] [Revised: 11/26/2022] [Indexed: 12/14/2022]
Abstract
A thrombus is a blood clot that forms in the lumen of an artery or vein, restricting blood flow and causing clinical symptoms. Thrombosis is associated with many life-threatening cardiovascular diseases. However, current clinical therapeutic technologies still have many problems in targeting, enrichment, penetration, and safety to meet the thrombosis treatment needs. Therefore, researchers devote themselves to developing nanosystems loaded with antithrombotic drugs to address this paradox in recent years. Herein, the existing thrombosis treatment technologies are first reviewed; and then, their advantages and disadvantages are outlined based on a brief discussion of thrombosis's definition and formation mechanism. Furthermore, the need and application cases for introducing nanotechnology are discussed, focusing on thrombus-specific targeted ligand modification technology and microenvironment-triggered responsive drug release technology. Then, nanomaterials that can be used to design antithrombotic nanotherapeutic systems are summarized. Moreover, a variety of drug delivery technologies driven by nanomotors in thrombosis therapy is also introduced. Last of all, a prospective discussion on the future development of nanotechnology for thrombosis therapy is highlighted.
Collapse
Affiliation(s)
- Shuyin Zhou
- National and Local Joint Engineering Research Center of Biomedical Functional Materials, School of Chemistry and Materials Science, Nanjing Normal University, Nanjing, 210023, China.,Department of Vascular Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China
| | - Wenbo Zhao
- National and Local Joint Engineering Research Center of Biomedical Functional Materials, School of Chemistry and Materials Science, Nanjing Normal University, Nanjing, 210023, China
| | - Jinglei Hu
- Kuang Yaming Honors School, Nanjing University, Nanjing, 210023, China
| | - Chun Mao
- National and Local Joint Engineering Research Center of Biomedical Functional Materials, School of Chemistry and Materials Science, Nanjing Normal University, Nanjing, 210023, China
| | - Min Zhou
- Department of Vascular Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China
| |
Collapse
|
2
|
Shi T, Miller EJ. Novel Radiotracers for Molecular Imaging of Myocardial Inflammation: an Update Focused on Clinical Translation of Non-18F-FDG Radiotracers. CURRENT CARDIOVASCULAR IMAGING REPORTS 2023; 16:1-9. [PMID: 36926261 PMCID: PMC9996562 DOI: 10.1007/s12410-023-09574-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/26/2023] [Indexed: 03/11/2023]
Abstract
Purpose of Review The purpose of this paper is to provide a focused update on recent advances in non-18F-FDG radiotracers for myocardial inflammatory diseases, with a focus on cardiac sarcoidosis and myocarditis. Recent Findings Novel radiotracers targeting molecular features of inflammation have the potential to visualize underlying molecular mechanisms key to the pathogenesis of inflammatory cardiomyopathies such as sarcoidosis and myocarditis. These radiotracers may provide unique opportunities for improved mechanistic insight, higher specificity, and better quantification of disease activity, as well as potential for guidance and monitoring of immunomodulatory therapies. Summary Novel radiotracers provide unique possibilities in diagnosis, prognostic performance, and therapy guidance for cardiac sarcoidosis and myocarditis.
Collapse
Affiliation(s)
- Tiantian Shi
- Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT USA
| | - Edward J Miller
- Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT USA
| |
Collapse
|
3
|
Iqbal MW, Riaz T, Mahmood S, Bilal M, Manzoor MF, Qamar SA, Qi X. Fucoidan-based nanomaterial and its multifunctional role for pharmaceutical and biomedical applications. Crit Rev Food Sci Nutr 2022; 64:354-380. [PMID: 35930305 DOI: 10.1080/10408398.2022.2106182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Fucoidans are promising sulfated polysaccharides isolated from marine sources that have piqued the interest of scientists in recent years due to their widespread use as a bioactive substance. Bioactive coatings and films, unsurprisingly, have seized these substances to create novel, culinary, therapeutic, and diagnostic bioactive nanomaterials. The applications of fucoidan and its composite nanomaterials have a wide variety of food as well as pharmacological properties, including anti-oxidative, anti-inflammatory, anti-cancer, anti-thrombic, anti-coagulant, immunoregulatory, and anti-viral properties. Blends of fucoidan with other biopolymers such as chitosan, alginate, curdlan, starch, etc., have shown promising coating and film-forming capabilities. A blending of biopolymers is a recommended approach to improve their anticipated properties. This review focuses on the fundamental knowledge and current development of fucoidan, fucoidan-based composite material for bioactive coatings and films, and their biological properties. In this article, fucoidan-based edible bioactive coatings and films expressed excellent mechanical strength that can prolong the shelf-life of food products and maintain their biodegradability. Additionally, these coatings and films showed numerous applications in the biomedical field and contribute to the economy. We hope this review can deliver the theoretical basis for the development of fucoidan-based bioactive material and films.
Collapse
Affiliation(s)
| | - Tahreem Riaz
- School of Food and Biological Engineering, Jiangsu University, Zhenjiang, China
- State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu, China
| | - Shahid Mahmood
- School of Food and Biological Engineering, Jiangsu University, Zhenjiang, China
| | - Muhammad Bilal
- School of Life Science and Food Engineering, Huaiyin Institute of Technology, Huaian, China
| | | | - Sarmad Ahmad Qamar
- Institute of Organic and Polymeric Materials, National Taipei University of Technology, Taipei, Taiwan
| | - Xianghui Qi
- School of Food and Biological Engineering, Jiangsu University, Zhenjiang, China
| |
Collapse
|
4
|
Sun W, Zheng J, Gao Y. Targeting Platelet Activation in Abdominal Aortic Aneurysm: Current Knowledge and Perspectives. Biomolecules 2022; 12:biom12020206. [PMID: 35204706 PMCID: PMC8961578 DOI: 10.3390/biom12020206] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2021] [Revised: 01/21/2022] [Accepted: 01/22/2022] [Indexed: 01/28/2023] Open
Abstract
Abdominal aortic aneurysm (AAA) is a potentially fatal vascular disease that involves complex multifactorial hemodynamic, thrombotic, inflammatory, and aortic wall remodeling processes. However, its mechanisms are incompletely understood. It has become increasingly clear that platelets are involved in pathological processes of vascular diseases beyond their role in hemostasis and thrombosis. Platelet activation with membrane receptors and secreted mediators promotes thrombus formation and the accumulation of inflammatory cells, which may play an important role in the development of AAA by destroying the structural integrity and stability of the vessel wall. Turbulent blood flow in aortic aneurysms promotes platelet activation and aggregation. Platelet count and heterogeneity are important predictive, diagnostic, and prognostic indicators of AAA. We summarize the relationship between platelet activation and AAA development and propose future research directions and possible clinical applications.
Collapse
Affiliation(s)
- Weiliang Sun
- Institute of Clinical Medicine Sciences, China-Japan Friendship Hospital, 2 Yinghua Dongjie, Chaoyang District, Beijing 100029, China;
| | - Jingang Zheng
- Department of Cardiology, China-Japan Friendship Hospital, 2 Yinghua Dongjie, Chaoyang District, Beijing 100029, China;
| | - Yanxiang Gao
- Department of Cardiology, China-Japan Friendship Hospital, 2 Yinghua Dongjie, Chaoyang District, Beijing 100029, China;
- Correspondence:
| |
Collapse
|
5
|
Yao Y, Yim EKF. Fucoidan for cardiovascular application and the factors mediating its activities. Carbohydr Polym 2021; 270:118347. [PMID: 34364596 PMCID: PMC10429693 DOI: 10.1016/j.carbpol.2021.118347] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Revised: 06/12/2021] [Accepted: 06/12/2021] [Indexed: 12/17/2022]
Abstract
Fucoidan is a sulfated polysaccharide with various bioactivities. The application of fucoidan in cancer treatment, wound healing, and food industry has been extensively studied. However, the therapeutic value of fucoidan in cardiovascular diseases has been less explored. Increasing number of investigations in the past years have demonstrated the effects of fucoidan on cardiovascular system. In this review, we will focus on the bioactivities related to cardiovascular applications, for example, the modulation functions of fucoidan on coagulation system, inflammation, and vascular cells. Factors mediating those activities will be discussed in detail. Current therapeutic strategies and future opportunities and challenges will be provided to inspire and guide further research.
Collapse
Affiliation(s)
- Yuan Yao
- Department of Chemical Engineering, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada.
| | - Evelyn K F Yim
- Department of Chemical Engineering, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada; Waterloo Institute for Nanotechnology, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada; Center for Biotechnology and Bioengineering, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada.
| |
Collapse
|
6
|
Zenych A, Jacqmarcq C, Aid R, Fournier L, Forero Ramirez LM, Chaubet F, Bonnard T, Vivien D, Letourneur D, Chauvierre C. Fucoidan-functionalized polysaccharide submicroparticles loaded with alteplase for efficient targeted thrombolytic therapy. Biomaterials 2021; 277:121102. [PMID: 34482087 DOI: 10.1016/j.biomaterials.2021.121102] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Revised: 06/22/2021] [Accepted: 08/25/2021] [Indexed: 01/22/2023]
Abstract
Intravenous administration of fibrinolytic drugs is the standard treatment of acute thrombotic diseases. However, current fibrinolytics exhibit limited clinical efficacy because of their short plasma half-lives and might trigger hemorrhagic transformations. Therefore, it is mandatory to develop innovative nanomedicine-based solutions for more efficient and safer thrombolysis with biocompatible and biodegradable thrombus-targeted nanocarrier. Herein, fucoidan-functionalized hydrogel polysaccharide submicroparticles with high biocompatibility are elaborated by the inverse miniemulsion/crosslinking method. They are loaded with the gold standard fibrinolytic - alteplase - to direct site-specific fibrinolysis due to nanomolar interactions between fucoidan and P-selectin overexpressed on activated platelets and endothelial cells in the thrombus area. The thrombus targeting properties of these particles are validated in a microfluidic assay containing recombinant P-selectin and activated platelets under arterial and venous blood shear rates as well as in vivo. The experiments on the murine model of acute thromboembolic ischemic stroke support this product's therapeutic efficacy, revealing a faster recanalization rate in the middle cerebral artery than with free alteplase, which reduces post-ischemic cerebral infarct lesions and blood-brain barrier permeability. Altogether, this proof-of-concept study demonstrates the potential of a biomaterial-based targeted nanomedicine for the precise treatment of acute thrombotic events, such as ischemic stroke.
Collapse
Affiliation(s)
- Alina Zenych
- Université de Paris, Université Sorbonne Paris Nord, UMR S1148, INSERM, F-75018, Paris, France
| | - Charlène Jacqmarcq
- INSERM U1237 Physiopathology and Imaging of Neurological Disorders (PhIND), Institut Blood and Brain @ Caen Normandie (BB@C), GIP Cyceron, 14074, Caen, France
| | - Rachida Aid
- Université de Paris, Université Sorbonne Paris Nord, UMR S1148, INSERM, F-75018, Paris, France; Université de Paris, FRIM, UMS 034, INSERM, F-75018, Paris, France
| | - Louise Fournier
- Université de Paris, Université Sorbonne Paris Nord, UMR S1148, INSERM, F-75018, Paris, France
| | - Laura M Forero Ramirez
- Université de Paris, Université Sorbonne Paris Nord, UMR S1148, INSERM, F-75018, Paris, France
| | - Frédéric Chaubet
- Université de Paris, Université Sorbonne Paris Nord, UMR S1148, INSERM, F-75018, Paris, France
| | - Thomas Bonnard
- INSERM U1237 Physiopathology and Imaging of Neurological Disorders (PhIND), Institut Blood and Brain @ Caen Normandie (BB@C), GIP Cyceron, 14074, Caen, France
| | - Denis Vivien
- INSERM U1237 Physiopathology and Imaging of Neurological Disorders (PhIND), Institut Blood and Brain @ Caen Normandie (BB@C), GIP Cyceron, 14074, Caen, France; Department of Clinical Research, Caen Normandie University Hospital (CHU), 14074, Caen, France
| | - Didier Letourneur
- Université de Paris, Université Sorbonne Paris Nord, UMR S1148, INSERM, F-75018, Paris, France
| | - Cédric Chauvierre
- Université de Paris, Université Sorbonne Paris Nord, UMR S1148, INSERM, F-75018, Paris, France.
| |
Collapse
|
7
|
Wang Z, Huang H, Chen Y, Zheng Y. Current Strategies for Microbubble-Based Thrombus Targeting: Activation-Specific Epitopes and Small Molecular Ligands. Front Bioeng Biotechnol 2021; 9:699450. [PMID: 34336810 PMCID: PMC8322734 DOI: 10.3389/fbioe.2021.699450] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Accepted: 06/22/2021] [Indexed: 11/26/2022] Open
Abstract
Microbubbles with enhanced ultrasound represent a potentially potent evolution to the administration of a free drug in the treatment of thrombotic diseases. Conformational and expressional changes of several thrombotic biological components during active coagulation provide epitopes that allow site-specific delivery of microbubble-based agents to the thrombus for theranostic purpose. Through the interaction with these epitopes, emerging high-affinity small molecular ligands are able to selectively target the thrombi with tremendous advantages over traditional antibody-based strategy. In this mini-review, we summarize recent novel strategies for microbubble-based targeting of thrombus through epitopes located at activated platelets and fibrin. We also discuss the challenges of current targeting modalities and supramolecular carrier systems for their translational use in thrombotic pathologies.
Collapse
Affiliation(s)
- Zhaojian Wang
- Department of Vascular Surgery, Peking Union Medical College Hospital, Beijing, China
| | - Huaigu Huang
- Department of Vascular Surgery, Peking Union Medical College Hospital, Beijing, China
| | - Yuexin Chen
- Department of Vascular Surgery, Peking Union Medical College Hospital, Beijing, China
| | - Yuehong Zheng
- Department of Vascular Surgery, Peking Union Medical College Hospital, Beijing, China
| |
Collapse
|
8
|
Cheng TM, Li R, Kao YCJ, Hsu CH, Chu HL, Lu KY, Changou CA, Chang CC, Chang LH, Tsai ML, Mi FL. Synthesis and characterization of Gd-DTPA/fucoidan/peptide complex nanoparticle and in vitro magnetic resonance imaging of inflamed endothelial cells. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2020; 114:111064. [DOI: 10.1016/j.msec.2020.111064] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Revised: 04/25/2020] [Accepted: 05/05/2020] [Indexed: 01/10/2023]
|
9
|
Perkins LA, Anderson CJ, Novelli EM. Targeting P-Selectin Adhesion Molecule in Molecular Imaging: P-Selectin Expression as a Valuable Imaging Biomarker of Inflammation in Cardiovascular Disease. J Nucl Med 2019; 60:1691-1697. [PMID: 31601694 DOI: 10.2967/jnumed.118.225169] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Accepted: 10/04/2019] [Indexed: 12/20/2022] Open
Abstract
P-selectin is an adhesion molecule translocated to the surface of endothelial cells and platelets under inflammatory stimuli, and its potential as a biomarker in inflammatory conditions has driven preclinical studies to investigate its application for molecular imaging of inflammation. Clinical imaging of P-selectin expression for disease characterization could have an important role in stratifying patients and determining treatment strategies. The objective of this review is to outline the role of P-selectin in cardiovascular inflammatory conditions and its translation as an early inflammatory biomarker for several molecular imaging modalities for diagnostic purposes and therapeutic planning.
Collapse
Affiliation(s)
- Lydia A Perkins
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Carolyn J Anderson
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Enrico M Novelli
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
| |
Collapse
|
10
|
Fitton HJ, Stringer DS, Park AY, Karpiniec SN. Therapies from Fucoidan: New Developments. Mar Drugs 2019; 17:E571. [PMID: 31601041 PMCID: PMC6836154 DOI: 10.3390/md17100571] [Citation(s) in RCA: 88] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2019] [Revised: 10/04/2019] [Accepted: 10/04/2019] [Indexed: 12/16/2022] Open
Abstract
Since our last review in 2015, the study and use of fucoidan has extended in several research areas. Clinical use of fucoidan for the treatment of renal disease has become available and human safety studies have been undertaken on radiolabeled fucoidan for the purpose of imaging thrombi. Fucoidan has been incorporated into an increasing number of commercially available supplements and topical treatments. In addition, new measuring techniques are now available to assess the biologically relevant uptake of fucoidans and to assist in production. Microbiome modulation and anti-pathogenic effects are increasingly promising applications for fucoidans, due to the need for alternative approaches to antibiotic use in the food chain. This review outlines promising new developments in fucoidan research, including potential future therapeutic use.
Collapse
Affiliation(s)
- Helen J Fitton
- Marinova Pty Ltd., 249 Kennedy Drive, Cambridge, Tasmania 7170, Australia.
| | - Damien S Stringer
- Marinova Pty Ltd., 249 Kennedy Drive, Cambridge, Tasmania 7170, Australia
| | - Ah Young Park
- Marinova Pty Ltd., 249 Kennedy Drive, Cambridge, Tasmania 7170, Australia
| | - Samuel N Karpiniec
- Marinova Pty Ltd., 249 Kennedy Drive, Cambridge, Tasmania 7170, Australia
| |
Collapse
|
11
|
Jiang T, Chen L, Huang Y, Wang J, Xu M, Zhou S, Gu X, Chen Y, Liang K, Pei Y, Song Q, Liu S, Ma F, Lu H, Gao X, Chen J. Metformin and Docosahexaenoic Acid Hybrid Micelles for Premetastatic Niche Modulation and Tumor Metastasis Suppression. NANO LETTERS 2019; 19:3548-3562. [PMID: 31026397 DOI: 10.1021/acs.nanolett.9b00495] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Metastasis is the major cause of high mortality in cancer patients; thus, blocking the metastatic process is of critical importance for cancer treatments. The premetastatic niche, a specialized microenvironment with aberrant changes related to inflammation, allows the colonization of circulating tumor cells (CTCs) and serves as a potential target for metastasis prevention. However, little effort has been dedicated to developing nanomedicine to amend the premetastatic niche. Here this study reports a premetastatic niche-targeting micelle for the modulation of premetastatic microenvironments and suppression of tumor metastasis. The micelles are self-assembled with the oleate carbon chain derivative of metformin and docosahexaenoic acid, two anti-inflammatory agents with low toxicity, and coated with fucoidan for premetastatic niche-targeting. The obtained functionalized micelles (FucOMDs) exhibit an excellent blood circulation profile and premetastatic site-targeting efficiency, inhibit CTC adhesion to activated endothelial cells, alleviate lung vascular permeability, and reverse the aberrant expression of key marker proteins in premetastatic niches. As a result, FucOMDs prevent metastasis formation and efficiently suppress both primary-tumor growth and metastasis formation when combined with targeted chemotherapy. Collectively, the findings here provide proof of concept that the modulation of the premetastatic niche with targeted anti-inflammatory agents provides a potent platform and a safe and clinical translational option for the suppression of tumor metastasis.
Collapse
Affiliation(s)
- Tianze Jiang
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy , Fudan University , Lane 826, Zhangheng Road , Shanghai 201203 , PR China
| | - Liang Chen
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy , Fudan University , Lane 826, Zhangheng Road , Shanghai 201203 , PR China
| | - Yukun Huang
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy , Fudan University , Lane 826, Zhangheng Road , Shanghai 201203 , PR China
| | - Jiahao Wang
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy , Fudan University , Lane 826, Zhangheng Road , Shanghai 201203 , PR China
| | - Minjun Xu
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy , Fudan University , Lane 826, Zhangheng Road , Shanghai 201203 , PR China
| | - Songlei Zhou
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy , Fudan University , Lane 826, Zhangheng Road , Shanghai 201203 , PR China
| | - Xiao Gu
- Department of Pharmacology and Chemical Biology , Shanghai Jiao Tong University School of Medicine , 280 South Chongqing Road , Shanghai 200025 , PR China
| | - Yu Chen
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy , Fudan University , Lane 826, Zhangheng Road , Shanghai 201203 , PR China
| | - Kaifan Liang
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy , Fudan University , Lane 826, Zhangheng Road , Shanghai 201203 , PR China
| | - Yuanyuan Pei
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy , Fudan University , Lane 826, Zhangheng Road , Shanghai 201203 , PR China
| | - Qingxiang Song
- Department of Pharmacology and Chemical Biology , Shanghai Jiao Tong University School of Medicine , 280 South Chongqing Road , Shanghai 200025 , PR China
| | - Shanshan Liu
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy , Fudan University , Lane 826, Zhangheng Road , Shanghai 201203 , PR China
| | - Fenfen Ma
- Department of Pharmacy, Shanghai Pudong Hospital , Fudan University , 2800 Gongwei Road , Shanghai 201399 , PR China
| | - Huiping Lu
- Department of Pharmacy, Shanghai Pudong Hospital , Fudan University , 2800 Gongwei Road , Shanghai 201399 , PR China
| | - Xiaoling Gao
- Department of Pharmacology and Chemical Biology , Shanghai Jiao Tong University School of Medicine , 280 South Chongqing Road , Shanghai 200025 , PR China
| | - Jun Chen
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy , Fudan University , Lane 826, Zhangheng Road , Shanghai 201203 , PR China
- Department of Pharmacy, Shanghai Pudong Hospital , Fudan University , 2800 Gongwei Road , Shanghai 201399 , PR China
| |
Collapse
|
12
|
Antunes JC, Benarroch L, Moraes FC, Juenet M, Gross MS, Aubart M, Boileau C, Caligiuri G, Nicoletti A, Ollivier V, Chaubet F, Letourneur D, Chauvierre C. Core-Shell Polymer-Based Nanoparticles Deliver miR-155-5p to Endothelial Cells. MOLECULAR THERAPY. NUCLEIC ACIDS 2019; 17:210-222. [PMID: 31265949 PMCID: PMC6610682 DOI: 10.1016/j.omtn.2019.05.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Revised: 05/20/2019] [Accepted: 05/20/2019] [Indexed: 12/12/2022]
Abstract
Heart failure occurs in over 30% of the worldwide population and most commonly originates from cardiovascular diseases such as myocardial infarction. microRNAs (miRNAs) target and silence specific mRNAs, thereby regulating gene expression. Because the endogenous miR-155-5p has been ascribed to vasculoprotection, loading it onto positively charged, core-shell poly(isobutylcyanoacrylate) (PIBCA)-polysaccharide nanoparticles (NPs) was attempted. NPs showed a decrease (p < 0.0001) in surface electrical charge (ζ potential), with negligible changes in size or shape when loaded with the anionic miR-155-5p. Presence of miR-155-5p in loaded NPs was further quantified. Cytocompatibility up to 100 μg/mL of NPs for 2 days with human coronary artery endothelial cells (hCAECs) was documented. NPs were able to enter hCAECs and were localized in the endoplasmic reticulum (ER). Expression of miR-155-5p was increased within the cells by 75-fold after 4 hours of incubation (p < 0.05) and was still noticeable at day 2. Differences between loaded NP-cultured cells and free miRNA, at days 1 (p < 0.05) and 2 (p < 0.001) suggest the ability of prolonged load release in physiological conditions. Expression of miR-155-5p downstream target BACH1 was decreased in the cells by 4-fold after 1 day of incubation (p < 0.05). This study is a first proof of concept that miR-155-5p can be loaded onto NPs and remain intact and biologically active in endothelial cells (ECs). These nanosystems could potentially increase an endogenous cytoprotective response and decrease damage within infarcted hearts.
Collapse
Affiliation(s)
- Joana C Antunes
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Louise Benarroch
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Fernanda C Moraes
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Maya Juenet
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Marie-Sylvie Gross
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Mélodie Aubart
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Catherine Boileau
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Giuseppina Caligiuri
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Antonino Nicoletti
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Véronique Ollivier
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Frédéric Chaubet
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Didier Letourneur
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France
| | - Cédric Chauvierre
- Université de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France.
| |
Collapse
|
13
|
Li B, Aid-Launais R, Labour MN, Zenych A, Juenet M, Choqueux C, Ollivier V, Couture O, Letourneur D, Chauvierre C. Functionalized polymer microbubbles as new molecular ultrasound contrast agent to target P-selectin in thrombus. Biomaterials 2019; 194:139-150. [DOI: 10.1016/j.biomaterials.2018.12.023] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2018] [Revised: 11/28/2018] [Accepted: 12/20/2018] [Indexed: 12/30/2022]
|
14
|
Geskovski N, Sazdovska SD, Goracinova K. Macroalgal Polysaccharides in Biomimetic Nanodelivery Systems. Curr Pharm Des 2019; 25:1265-1289. [PMID: 31020934 DOI: 10.2174/1381612825666190423155116] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Accepted: 04/15/2019] [Indexed: 02/07/2023]
Abstract
BACKGROUND Imitating nature in the design of bio-inspired drug delivery systems resulted in several success stories. However, the practical application of biomimicry is still largely unrealized owing to the fact that we tend to copy the shape more often than the whole biology. Interesting chemistry of polysaccharides provides endless possibilities for drug complex formation and creation of delivery systems with diverse morphological and surface properties. However, the type of biological response, which may be induced by these systems, remains largely unexploited. METHODS Considering the most current research for the given topic, in this review, we will try to present the integrative approaches for the design of biomimetic DDS's with improved therapeutic or theranostic effects based on different algal polysaccharides that exert multiple biological functions. RESULTS Algal polysaccharides may provide building blocks for bioinspired drug delivery systems capable of supporting the mechanical properties of nanomedicines and mimicking various biological processes by molecular interactions at the nanoscale. Numerous research studies demonstrate the efficacy and safety of multifunctional nanoparticles integrating several functions in one delivery system, composed of alginate, carrageenan, ulvan, fucoidan and their derivatives, intended to be used as bioartificial microenvironment or for diagnosis and therapy of different diseases. CONCLUSION Nanodimensional structure of polysaccharide DDS's shows substantial influence on the bioactive motifs potential availability for interaction with a variety of biomolecules and cells. Evaluation of the nano dimensional structure-activity relationship is crucial for unlocking the full potential of the future application of polysaccharide bio-mimicking DDS in modern diagnostic and therapeutic procedures.
Collapse
Affiliation(s)
- Nikola Geskovski
- Institute of Pharmaceutical Technology, Faculty of Pharmacy, University of Ss Cyril and Methodius, Skopje, Republic of North Macedonia
| | - Simona Dimchevska Sazdovska
- Institute of Pharmaceutical Technology, Faculty of Pharmacy, University of Ss Cyril and Methodius, Skopje, Republic of North Macedonia
| | | |
Collapse
|
15
|
Shamay Y, Elkabets M, Li H, Shah J, Brook S, Wang F, Adler K, Baut E, Scaltriti M, Jena PV, Gardner EE, Poirier JT, Rudin CM, Baselga J, Haimovitz-Friedman A, Heller DA. P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Sci Transl Med 2017; 8:345ra87. [PMID: 27358497 DOI: 10.1126/scitranslmed.aaf7374] [Citation(s) in RCA: 139] [Impact Index Per Article: 19.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2016] [Accepted: 06/08/2016] [Indexed: 12/15/2022]
Abstract
Disseminated tumors are poorly accessible to nanoscale drug delivery systems because of the vascular barrier, which attenuates extravasation at the tumor site. We investigated P-selectin, a molecule expressed on activated vasculature that facilitates metastasis by arresting tumor cells at the endothelium, for its potential to target metastases by arresting nanomedicines at the tumor endothelium. We found that P-selectin is expressed on cancer cells in many human tumors. To develop a targeted drug delivery platform, we used a fucosylated polysaccharide with nanomolar affinity to P-selectin. The nanoparticles targeted the tumor microenvironment to localize chemotherapeutics and a targeted MEK (mitogen-activated protein kinase kinase) inhibitor at tumor sites in both primary and metastatic models, resulting in superior antitumor efficacy. In tumors devoid of P-selectin, we found that ionizing radiation guided the nanoparticles to the disease site by inducing P-selectin expression. Radiation concomitantly produced an abscopal-like phenomenon wherein P-selectin appeared in unirradiated tumor vasculature, suggesting a potential strategy to target disparate drug classes to almost any tumor.
Collapse
Affiliation(s)
- Yosi Shamay
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Moshe Elkabets
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel
| | - Hongyan Li
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Janki Shah
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Samuel Brook
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Feng Wang
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Department of Oncology, Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, NY 10461, USA
| | - Keren Adler
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Brandeis University, Waltham, MA 02453, USA
| | - Emily Baut
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA
| | - Maurizio Scaltriti
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Prakrit V Jena
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Eric E Gardner
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Pharmacology Graduate Training Program, Johns Hopkins University, Baltimore, MD 21287, USA
| | - John T Poirier
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Charles M Rudin
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - José Baselga
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | | | - Daniel A Heller
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA.
| |
Collapse
|
16
|
Juenet M, Aid-Launais R, Li B, Berger A, Aerts J, Ollivier V, Nicoletti A, Letourneur D, Chauvierre C. Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting P-selectin. Biomaterials 2017; 156:204-216. [PMID: 29216534 DOI: 10.1016/j.biomaterials.2017.11.047] [Citation(s) in RCA: 101] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2017] [Revised: 11/21/2017] [Accepted: 11/27/2017] [Indexed: 12/19/2022]
Abstract
Injection of recombinant tissue plasminogen activator (rt-PA) is the standard drug treatment for thrombolysis. However, rt-PA shows risk of hemorrhages and limited efficiency even at high doses. Polysaccharide-poly(isobutylcyanoacrylate) nanoparticles functionalized with fucoidan and loaded with rt-PA were designed to accumulate on the thrombus. Fucoidan has a nanomolar affinity for the P-selectin expressed by activated platelets in the thrombus. Solid spherical fluorescent nanoparticles with a hydrodynamic diameter of 136 ± 4 nm were synthesized by redox radical emulsion polymerization. The clinical rt-PA formulation was successfully loaded by adsorption on aminated nanoparticles and able to be released in vitro. We validated the in vitro fibrinolytic activity and binding under flow to both recombinant P-selectin and activated platelet aggregates. The thrombolysis efficiency was demonstrated in a mouse model of venous thrombosis by monitoring the platelet density with intravital microscopy. This study supports the hypothesis that fucoidan-nanoparticles improve the rt-PA efficiency. This work establishes the proof-of-concept of fucoidan-based carriers for targeted thrombolysis.
Collapse
Affiliation(s)
- Maya Juenet
- INSERM, U1148, Laboratory for Vascular Translational Science, X. Bichat Hospital, 46 rue Henri Huchard, 75018, Paris, France; Paris Diderot University, Paris 13 University, Sorbonne Paris Cité, Paris, France
| | - Rachida Aid-Launais
- INSERM, U1148, Laboratory for Vascular Translational Science, X. Bichat Hospital, 46 rue Henri Huchard, 75018, Paris, France; Paris Diderot University, Paris 13 University, Sorbonne Paris Cité, Paris, France; FRIM, INSERM UMS 034 Paris Diderot University, X. Bichat Hospital, 75018, Paris, France
| | - Bo Li
- INSERM, U1148, Laboratory for Vascular Translational Science, X. Bichat Hospital, 46 rue Henri Huchard, 75018, Paris, France; Paris Diderot University, Paris 13 University, Sorbonne Paris Cité, Paris, France
| | - Alice Berger
- INSERM, U1148, Laboratory for Vascular Translational Science, X. Bichat Hospital, 46 rue Henri Huchard, 75018, Paris, France; Paris Diderot University, Paris 13 University, Sorbonne Paris Cité, Paris, France
| | - Joël Aerts
- FRIM, INSERM UMS 034 Paris Diderot University, X. Bichat Hospital, 75018, Paris, France
| | - Véronique Ollivier
- INSERM, U1148, Laboratory for Vascular Translational Science, X. Bichat Hospital, 46 rue Henri Huchard, 75018, Paris, France; Paris Diderot University, Paris 13 University, Sorbonne Paris Cité, Paris, France
| | - Antonino Nicoletti
- INSERM, U1148, Laboratory for Vascular Translational Science, X. Bichat Hospital, 46 rue Henri Huchard, 75018, Paris, France; Paris Diderot University, Paris 13 University, Sorbonne Paris Cité, Paris, France
| | - Didier Letourneur
- INSERM, U1148, Laboratory for Vascular Translational Science, X. Bichat Hospital, 46 rue Henri Huchard, 75018, Paris, France; Paris Diderot University, Paris 13 University, Sorbonne Paris Cité, Paris, France
| | - Cédric Chauvierre
- INSERM, U1148, Laboratory for Vascular Translational Science, X. Bichat Hospital, 46 rue Henri Huchard, 75018, Paris, France; Paris Diderot University, Paris 13 University, Sorbonne Paris Cité, Paris, France.
| |
Collapse
|
17
|
Henry N, Clouet J, Fragale A, Griveau L, Chédeville C, Véziers J, Weiss P, Le Bideau J, Guicheux J, Le Visage C. Pullulan microbeads/Si-HPMC hydrogel injectable system for the sustained delivery of GDF-5 and TGF-β1: new insight into intervertebral disc regenerative medicine. Drug Deliv 2017; 24:999-1010. [PMID: 28645219 PMCID: PMC8241148 DOI: 10.1080/10717544.2017.1340362] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Revised: 05/31/2017] [Accepted: 06/06/2017] [Indexed: 12/16/2022] Open
Abstract
Discogenic low back pain is considered a major health concern and no etiological treatments are today available to tackle this disease. To clinically address this issue at early stages, there is a rising interest in the stimulation of local cells by in situ injection of growth factors targeting intervertebral disc (IVD) degenerative process. Despite encouraging safety and tolerability results in clinic, growth factors efficacy may be further improved. To this end, the use of a delivery system allowing a sustained release, while protecting growth factors from degradation appears of particular interest. We propose herein the design of a new injectable biphasic system, based on the association of pullulan microbeads (PMBs) into a cellulose-based hydrogel (Si-HPMC), for the TGF-β1 and GDF-5 growth factors sustained delivery. We present for the first time the design and mechanical characterization of both the PMBs and the called biphasic system (PMBs/Si-HPMC). Their loading and release capacities were also studied and we were able to demonstrate a sustained release of both growth factors, for up to 28 days. Noteworthy, the growth factors biological activity on human cells was maintained. Altogether, these data suggest that this PMBs/Si-HPMC biphasic system may be a promising candidate for the development of an innovative bioactive delivery system for IVD regenerative medicine.
Collapse
Affiliation(s)
- Nina Henry
- INSERM, UMRS 1229, RMeS “Regenerative Medicine and Skeleton”, Team STEP “Skeletal Physiopathology and Joint Regenerative Medicine”, Nantes, France
- Institut des Matériaux Jean Rouxel (IMN), Université de Nantes, CNRS, Nantes, France
- UFR Odontologie, Université de Nantes, Nantes, France
| | - Johann Clouet
- INSERM, UMRS 1229, RMeS “Regenerative Medicine and Skeleton”, Team STEP “Skeletal Physiopathology and Joint Regenerative Medicine”, Nantes, France
- UFR Odontologie, Université de Nantes, Nantes, France
- CHU Nantes, PHU 11 Pharmacie, Pharmacie Centrale, Nantes, France
- UFR Sciences Biologiques et Pharmaceutiques, Université de Nantes, Nantes, France
| | - Audrey Fragale
- INSERM, UMRS 1229, RMeS “Regenerative Medicine and Skeleton”, Team STEP “Skeletal Physiopathology and Joint Regenerative Medicine”, Nantes, France
- UFR Odontologie, Université de Nantes, Nantes, France
| | - Louise Griveau
- INSERM, UMRS 1229, RMeS “Regenerative Medicine and Skeleton”, Team STEP “Skeletal Physiopathology and Joint Regenerative Medicine”, Nantes, France
| | - Claire Chédeville
- INSERM, UMRS 1229, RMeS “Regenerative Medicine and Skeleton”, Team STEP “Skeletal Physiopathology and Joint Regenerative Medicine”, Nantes, France
| | - Joëlle Véziers
- INSERM, UMRS 1229, RMeS “Regenerative Medicine and Skeleton”, Team STEP “Skeletal Physiopathology and Joint Regenerative Medicine”, Nantes, France
- UFR Odontologie, Université de Nantes, Nantes, France
- SC3M platform, UMS INSERM 016/CNRS 3556, SFR François Bonamy, Nantes, France
- CHU Nantes, PHU 4 OTONN, Nantes, France
| | - Pierre Weiss
- UFR Odontologie, Université de Nantes, Nantes, France
- INSERM, UMRS 1229, RMeS “Regenerative Medicine and Skeleton”, Team REGOS “Regenerative Medicine of Bone Tissues”, Nantes, France
| | - Jean Le Bideau
- Institut des Matériaux Jean Rouxel (IMN), Université de Nantes, CNRS, Nantes, France
| | - Jérôme Guicheux
- INSERM, UMRS 1229, RMeS “Regenerative Medicine and Skeleton”, Team STEP “Skeletal Physiopathology and Joint Regenerative Medicine”, Nantes, France
- UFR Odontologie, Université de Nantes, Nantes, France
- CHU Nantes, PHU 4 OTONN, Nantes, France
| | - Catherine Le Visage
- INSERM, UMRS 1229, RMeS “Regenerative Medicine and Skeleton”, Team STEP “Skeletal Physiopathology and Joint Regenerative Medicine”, Nantes, France
- UFR Odontologie, Université de Nantes, Nantes, France
| |
Collapse
|
18
|
Suffee N, Le Visage C, Hlawaty H, Aid-Launais R, Vanneaux V, Larghero J, Haddad O, Oudar O, Charnaux N, Sutton A. Pro-angiogenic effect of RANTES-loaded polysaccharide-based microparticles for a mouse ischemia therapy. Sci Rep 2017; 7:13294. [PMID: 29038476 PMCID: PMC5643514 DOI: 10.1038/s41598-017-13444-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Accepted: 08/09/2017] [Indexed: 12/20/2022] Open
Abstract
Peripheral arterial disease results from the chronic obstruction of arteries leading to critical hindlimb ischemia. The aim was to develop a new therapeutic strategy of revascularization by using biodegradable and biocompatible polysaccharides-based microparticles (MP) to treat the mouse hindlimb ischemia. For this purpose, we deliver the pro-angiogenic chemokine Regulated upon Activation, Normal T-cell Expressed and Secreted (RANTES)/CCL5 in the mouse ischemic hindlimb, in solution or incorporated into polysaccharide-based microparticles. We demonstrate that RANTES-loaded microparticles improve the clinical score, induce the revascularization and the muscle regeneration in injured mice limb. To decipher the mechanisms underlying RANTES effects in vivo, we demonstrate that RANTES increases the spreading, the migration of human endothelial progenitor cells (EPC) and the formation of vascular network. The main receptors of RANTES i.e. CCR5, syndecan-4 and CD44 expressed at endothelial progenitor cell surface are involved in RANTES-induced in vitro biological effects on EPC. By using two RANTES mutants, [E66A]-RANTES with impaired ability to oligomerize, and [44AANA47]-RANTES mutated in the main RANTES-glycosaminoglycan binding site, we demonstrate that both chemokine oligomerization and binding site to glycosaminoglycans are essential for RANTES-induced angiogenesis in vitro. Herein we improved the muscle regeneration and revascularization after RANTES-loaded MP local injection in mice hindlimb ischemia.
Collapse
Affiliation(s)
- N Suffee
- INSERM, U1148, Laboratory for Vascular Translational Science, UFR SMBH, Université Paris 13, Sorbonne Paris Cité, Bobigny, France
| | - C Le Visage
- Inserm, UMR 1229, RMeS, Regenerative Medicine and Skeleton, Université de Nantes, ONIRIS, Nantes, France
| | - H Hlawaty
- INSERM, U1148, Laboratory for Vascular Translational Science, UFR SMBH, Université Paris 13, Sorbonne Paris Cité, Bobigny, France
| | - R Aid-Launais
- INSERM, U1148, Laboratory for Vascular Translational Science, UFR SMBH, Université Paris 13, Sorbonne Paris Cité, Bobigny, France
| | - V Vanneaux
- APHP, Hôpital Saint-Louis, Unité de Thérapie Cellulaire, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, F-75475, Paris, France.,Inserm UMR1160 et CIC de Biothérapies, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France
| | - J Larghero
- APHP, Hôpital Saint-Louis, Unité de Thérapie Cellulaire, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, F-75475, Paris, France.,Inserm UMR1160 et CIC de Biothérapies, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France
| | - O Haddad
- INSERM, U1148, Laboratory for Vascular Translational Science, UFR SMBH, Université Paris 13, Sorbonne Paris Cité, Bobigny, France
| | - O Oudar
- INSERM, U1148, Laboratory for Vascular Translational Science, UFR SMBH, Université Paris 13, Sorbonne Paris Cité, Bobigny, France
| | - N Charnaux
- INSERM, U1148, Laboratory for Vascular Translational Science, UFR SMBH, Université Paris 13, Sorbonne Paris Cité, Bobigny, France.,Laboratoire de Biochimie, Hôpital Jean Verdier, AP-HP, Bondy, France
| | - A Sutton
- INSERM, U1148, Laboratory for Vascular Translational Science, UFR SMBH, Université Paris 13, Sorbonne Paris Cité, Bobigny, France. .,Laboratoire de Biochimie, Hôpital Jean Verdier, AP-HP, Bondy, France.
| |
Collapse
|
19
|
Liu J, Xu J, Zhou J, Zhang Y, Guo D, Wang Z. Fe 3O 4-based PLGA nanoparticles as MR contrast agents for the detection of thrombosis. Int J Nanomedicine 2017; 12:1113-1126. [PMID: 28223802 PMCID: PMC5310639 DOI: 10.2147/ijn.s123228] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Thrombotic disease is a great threat to human health, and early detection is particularly important. Magnetic resonance (MR) molecular imaging provides noninvasive imaging with the potential for early disease diagnosis. In this study, we developed Fe3O4-based poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) surface-modified with a cyclic Arg-Gly-Asp (cRGD) peptide as an MR contrast agent for the detection of thrombosis. The physical and chemical characteristics, biological toxicity, ability to target thrombi, and biodistribution of the NPs were studied. The Fe3O4-PLGA-cRGD NPs were constructed successfully, and hematologic and pathologic assays indicated no in vivo toxicity of the NPs. In a rat model of FeCl3-induced abdominal aorta thrombosis, the NPs readily and selectively accumulated on the surface of the thrombosis and under vascular endothelial cells ex vivo and in vivo. In the in vivo experiment, the biodistribution of the NPs suggested that the NPs might be internalized by the macrophages of the reticuloendothelial system in the liver and the spleen. The T2 signal decreased at the mural thrombus 10 min after injection and then gradually increased until 50 min. These results suggest that the NPs are suitable for in vivo molecular imaging of thrombosis under high shear stress conditions and represent a very promising MR contrast agent for sensitive and specific detection of thrombosis.
Collapse
Affiliation(s)
| | | | | | | | | | - Zhigang Wang
- Department of Ultrasound, Institute of Ultrasound Imaging, The Second Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, People's Republic of China
| |
Collapse
|
20
|
Sutapa BM, Dhruti A, Gopa RB. Pharmacological, pharmaceutical, cosmetic and diagnostic applications of sulfated polysaccharides from marine algae and bacteria. ACTA ACUST UNITED AC 2017. [DOI: 10.5897/ajpp2016.4695] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
21
|
Li B, Juenet M, Aid-Launais R, Maire M, Ollivier V, Letourneur D, Chauvierre C. Development of Polymer Microcapsules Functionalized with Fucoidan to Target P-Selectin Overexpressed in Cardiovascular Diseases. Adv Healthc Mater 2017; 6. [PMID: 27943662 DOI: 10.1002/adhm.201601200] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Indexed: 12/17/2022]
Abstract
New tools for molecular imaging and targeted therapy for cardiovascular diseases are still required. Herein, biodegradable microcapsules (MCs) made of polycyanoacrylate and polysaccharide and functionalized with fucoidan (Fuco-MCs) are designed as new carriers to target arterial thrombi overexpressing P-selectin. Physicochemical characterizations demonstrated that microcapsules have a core-shell structure and that fucoidan is present onto the surface of Fuco-MCs. Furthermore, their sizes range from 2 to 6 µm and they are stable on storage over 30 d at 4 °C. Flow cytometry experiments evidenced the binding of Fuco-MCs for human activated platelets as compared to MCs (mean fluorescence intensity: 12 008 vs. 9, p < 0.001) and its absence for nonactivated platelets (432). An in vitro flow adhesion assay showed high specific binding efficiency of Fuco-MCs to P-selectin and to activated platelet aggregates under arterial shear stress conditions. Moreover, both types of microcapsules reveal excellent compatibility with 3T3 cells in cytotoxicity assay. One hour after intravenous injection of microcapsules, histological analysis revealed that Fuco-MCs are localized in the rat abdominal aortic aneurysm thrombotic wall and that the binding in the healthy aorta is low. In conclusion, these microcapsules appear as promising carriers for targeting of tissues characterized by P-selectin overexpression and for their molecular imaging or treatment.
Collapse
Affiliation(s)
- Bo Li
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Maya Juenet
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Rachida Aid-Launais
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Murielle Maire
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Véronique Ollivier
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Didier Letourneur
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Cédric Chauvierre
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| |
Collapse
|
22
|
Brangsch J, Reimann C, Collettini F, Buchert R, Botnar RM, Makowski MR. Molecular Imaging of Abdominal Aortic Aneurysms. Trends Mol Med 2017; 23:150-164. [PMID: 28110838 DOI: 10.1016/j.molmed.2016.12.002] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2016] [Revised: 12/06/2016] [Accepted: 12/11/2016] [Indexed: 12/21/2022]
Abstract
Abdominal aortic aneurysms (AAAs) represent a vascular disease with severe complications. AAAs are currently the overall 10th leading cause of death in western countries and their incidence is rising. Although different diagnostic techniques are currently available in clinical practice, including ultrasound (US), magnetic resonance imaging (MRI), and computed tomography (CT), imaging-based prediction of life-threatening complications such as aneurysm-rupture remains challenging. Molecular imaging provides a novel diagnostic approach for in vivo visualization of biological processes and pathological alterations at a cellular and molecular level. Its overall aim is to improve our understanding of disease pathogenesis and to facilitate novel diagnostic pathways. This review outlines recent preclinical and clinical developments in molecular MRI, positron emission tomography (PET), and single-photon emission computed tomography (SPECT) for imaging of AAAs.
Collapse
Affiliation(s)
- Julia Brangsch
- Department of Radiology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany
| | - Carolin Reimann
- Department of Radiology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany
| | - Federico Collettini
- Department of Radiology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany
| | - Ralf Buchert
- Department of Radiology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany
| | - René M Botnar
- Department of Radiology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; Division of Imaging Sciences and Biomedical Engineering, King's College London, London WC2R 2LS, UK; Wellcome Trust and Engineering and Physical Sciences Research Council (EPSRC) Medical Engineering Centre, King's College London, London SE1 7EH, UK; British Heart Foundation (BHF) Centre of Excellence, King's College London, London SE5 9NU, UK; National Institute for Health Research (NIHR) Biomedical Research Centre, King's College London, London SE1 9RT, UK
| | - Marcus R Makowski
- Department of Radiology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; Division of Imaging Sciences and Biomedical Engineering, King's College London, London WC2R 2LS, UK.
| |
Collapse
|
23
|
Abstract
Thromboembolic disorders are a major cause of morbidity and mortality worldwide. The progress in noninvasive imaging techniques has led to the development of radionuclide imaging based on SPECT and PET approaches to observe molecular and cellular processes that may underlie the onset and progression of disease. The advantages of using normal and genetically modified small animal research have spurred the development of dedicated small animal imaging systems. Animal models of venous and arterial thrombosis are largely used and have improved our understanding of the etiology and pathogenesis of thrombosis. Here, we review the literature regarding nuclear imaging of thrombosis in mice and rats.
Collapse
Affiliation(s)
- Marie-Cécile Valéra
- a Inserm, U1048 and Université Toulouse III , I2MC, Toulouse , France.,b Faculté de Chirurgie Dentaire, Université de Toulouse III , Toulouse , France
| | - Bernard Payrastre
- a Inserm, U1048 and Université Toulouse III , I2MC, Toulouse , France.,c Laboratoire d'Hématologie CHU de Toulouse , Toulouse , France
| | - Olivier Lairez
- a Inserm, U1048 and Université Toulouse III , I2MC, Toulouse , France.,d Fédération des services de cardiologie, Département de Médecine Nucléaire Centre d'imagerie cardiaque, CHU de Toulouse , Toulouse , France
| |
Collapse
|
24
|
Chauvierre C, Letourneur D. The European project NanoAthero to fight cardiovascular diseases using nanotechnologies. Nanomedicine (Lond) 2016; 10:3391-400. [PMID: 26582278 DOI: 10.2217/nnm.15.170] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Cardiovascular diseases are the main causes of death in the world. Nanosystems with contrast agents or drugs appear as promising tools for early detection and treatments. NanoAthero, a large-scale 5-year project funded by the European Union FP7 gathers 16 partners from ten different countries to demonstrate the benefit of the use of nanoparticle technologies. Through the design and characterization of nanosystems, preclinical and clinical validations, toxicology, industrial development and production in good manufacturing practice forms, several studies are underway for plaque and stroke both for imaging and treatment. A clinical study was already completed using a good manufacturing practice liposomal formulation in patients with carotid atheroma. NanoAthero is a unique opportunity to open new strategies for the management of cardiovascular diseases.
Collapse
Affiliation(s)
- Cédric Chauvierre
- Inserm, U1148, Department of Cardiovascular Bio-Engineering, X Bichat Hospital, University Paris Diderot, 46 rue H Huchard, 75018 Paris, France.,Institut Galilée, University Paris 13, Sorbonne Paris Cité, 93430 Villetaneuse, France
| | - Didier Letourneur
- Inserm, U1148, Department of Cardiovascular Bio-Engineering, X Bichat Hospital, University Paris Diderot, 46 rue H Huchard, 75018 Paris, France.,Institut Galilée, University Paris 13, Sorbonne Paris Cité, 93430 Villetaneuse, France
| |
Collapse
|
25
|
Chollet L, Saboural P, Chauvierre C, Villemin JN, Letourneur D, Chaubet F. Fucoidans in Nanomedicine. Mar Drugs 2016; 14:E145. [PMID: 27483292 PMCID: PMC4999906 DOI: 10.3390/md14080145] [Citation(s) in RCA: 67] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Revised: 07/20/2016] [Accepted: 07/21/2016] [Indexed: 12/19/2022] Open
Abstract
Fucoidans are widespread cost-effective sulfated marine polysaccharides which have raised interest in the scientific community over last decades for their wide spectrum of bioactivities. Unsurprisingly, nanomedicine has grasped these compounds to develop innovative therapeutic and diagnostic nanosystems. The applications of fucoidans in nanomedicine as imaging agents, drug carriers or for their intrinsic properties are reviewed here after a short presentation of the main structural data and biological properties of fucoidans. The origin and the physicochemical specifications of fucoidans are summarized in order to discuss the strategy of fucoidan-containing nanosystems in Human health. Currently, there is a need for reproducible, well characterized fucoidan fractions to ensure significant progress.
Collapse
Affiliation(s)
- Lucas Chollet
- Inserm, U1148, LVTS, University Paris Diderot, X Bichat Hospital, F-75877 Paris, France.
- Galilée Institute, University Paris 13, Sorbonne Paris Cité, F-93430 Villetaneuse, France.
- Algues & Mer, Kernigou, F-29242 Ouessant, France.
| | - Pierre Saboural
- Inserm, U1148, LVTS, University Paris Diderot, X Bichat Hospital, F-75877 Paris, France.
- Galilée Institute, University Paris 13, Sorbonne Paris Cité, F-93430 Villetaneuse, France.
| | - Cédric Chauvierre
- Inserm, U1148, LVTS, University Paris Diderot, X Bichat Hospital, F-75877 Paris, France.
- Galilée Institute, University Paris 13, Sorbonne Paris Cité, F-93430 Villetaneuse, France.
| | | | - Didier Letourneur
- Inserm, U1148, LVTS, University Paris Diderot, X Bichat Hospital, F-75877 Paris, France.
- Galilée Institute, University Paris 13, Sorbonne Paris Cité, F-93430 Villetaneuse, France.
| | - Frédéric Chaubet
- Inserm, U1148, LVTS, University Paris Diderot, X Bichat Hospital, F-75877 Paris, France.
- Galilée Institute, University Paris 13, Sorbonne Paris Cité, F-93430 Villetaneuse, France.
| |
Collapse
|
26
|
Desbrée A, Bonnard T, Blanchardon E, Petiet A, Franck D, Chauvierre C, Le Visage C. Evaluation of Functionalized Polysaccharide Microparticles Dosimetry for SPECT Imaging Based on Biodistribution Data of Rats. Mol Imaging Biol 2016; 17:504-11. [PMID: 25537093 DOI: 10.1007/s11307-014-0812-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
PURPOSE Technetium-99 m (Tc-99 m)-labelled microparticles, functionalized with fucoidan to present a high affinity for P-Selectin, or [(99m)Tc] MP-fucoidan, were developed as a novel SPECT radiotracer for abdominal aortic aneurysm (AAA). As a prerequisite step forwards a clinical trial, the biodistribution and dosimetry of these [(99m)Tc] MP-fucoidan microparticles were performed in rats in order to estimate the absorbed and effective dose in humans. PROCEDURES Microparticles with a maximum hydrodynamic diameter of 4 μm were obtained by crosslinking polysaccharides dextran and pullulan. They were functionalized with fucoidan then radiolabelled with Tc-99 m. A mean labelling efficiency of 92 ± 1% was measured. [(99m)Tc] MP-fucoidan (43 ± 2 MBq) was injected to 24 rats via the penis vein. Rats were euthanized at 30, 60, 120 and 240 min after injection (4 rats at each time point). Samples of each organ, as well as the injected microparticle suspensions, were aliquoted for counting. Four animals were sacrificed for blood clearance studies and four were sacrificed for image analysis and quantification of the cortical, medullary, papillary kidney, and pelvis uptake. A compartmental model was realised using SAAM II and organ data were fitted. The area under the curve was then used to compute the residence times in each rat organs and converted to human residence time values. Absorbed and effective human doses in organs were estimated using (1) the OLINDA/EXM 1.1 software with the hermaphroditic mathematical phantoms and (2) the OEDIPE software associated to the MCNPX Monte Carlo code and the ICRP reference computational male and female phantoms, using the updated tissue weighting factors in the ICRP Publication 103. RESULTS The highest human residence times were found in the liver, kidneys, and urinary bladder wall. The largest doses were found in the kidneys and then in the urinary bladder wall and liver. The human effective doses were 6.06 μSv/MBq for the hermaphroditic mathematical phantom and 5.95 μSv/MBq for the ICRP adult reference computational phantom. CONCLUSIONS Animal-based human dose estimates support a future first-in-human testing of [(99m)Tc] MP-fucoidan following IV injection.
Collapse
Affiliation(s)
- Aurélie Desbrée
- Institut de Radioprotection et de Sûreté Nucléaire, Service de Dosimétrie Interne, 31 avenue de la Division Leclerc, 92260, Fontenay-aux-Roses, France,
| | | | | | | | | | | | | |
Collapse
|
27
|
Juenet M, Varna M, Aid-Launais R, Chauvierre C, Letourneur D. Nanomedicine for the molecular diagnosis of cardiovascular pathologies. Biochem Biophys Res Commun 2015; 468:476-84. [PMID: 26129770 DOI: 10.1016/j.bbrc.2015.06.138] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Accepted: 06/20/2015] [Indexed: 11/15/2022]
Abstract
Predicting acute clinical events caused by atherosclerotic plaque rupture remains a clinical challenge. Anatomic mapping of the vascular tree provided by standard imaging technologies is not always sufficient for a robust diagnosis. Yet biological mechanisms leading to unstable plaques have been identified and corresponding biomarkers have been described. Nanosystems charged with contrast agents and targeted towards these specific biomarkers have been developed for several types of imaging modalities. The first systems that have reached the clinic are ultrasmall superparamagnetic iron oxides for Magnetic Resonance Imaging. Their potential relies on their passive accumulation by predominant physiological mechanisms in rupture-prone plaques. Active targeting strategies are under development to improve their specificity and set up other types of nanoplatforms. Preclinical results show a huge potential of nanomedicine for cardiovascular diagnosis, as long as the safety of these nanosystems in the body is studied in depth.
Collapse
Affiliation(s)
- Maya Juenet
- Inserm, U1148, Cardiovascular Bio-Engineering, X. Bichat Hospital, 75018, Paris, France; Université Paris 13, Institut Galilée, Sorbonne Paris Cité, 75018, Paris, France
| | - Mariana Varna
- Inserm, U1148, Cardiovascular Bio-Engineering, X. Bichat Hospital, 75018, Paris, France; Université Paris 13, Institut Galilée, Sorbonne Paris Cité, 75018, Paris, France
| | - Rachida Aid-Launais
- Inserm, U1148, Cardiovascular Bio-Engineering, X. Bichat Hospital, 75018, Paris, France; Université Paris 13, Institut Galilée, Sorbonne Paris Cité, 75018, Paris, France
| | - Cédric Chauvierre
- Inserm, U1148, Cardiovascular Bio-Engineering, X. Bichat Hospital, 75018, Paris, France; Université Paris 13, Institut Galilée, Sorbonne Paris Cité, 75018, Paris, France.
| | - Didier Letourneur
- Inserm, U1148, Cardiovascular Bio-Engineering, X. Bichat Hospital, 75018, Paris, France; Université Paris 13, Institut Galilée, Sorbonne Paris Cité, 75018, Paris, France
| |
Collapse
|
28
|
Riou LM, Vanzetto G, Broisat A, Fagret D, Ghezzi C. Equivocal usefulness of FDG for the noninvasive imaging of abdominal aortic aneurysms. Eur J Nucl Med Mol Imaging 2014; 41:2307-9. [PMID: 25253269 DOI: 10.1007/s00259-014-2917-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Laurent M Riou
- INSERM, U1039, Radiopharmaceutiques Biocliniques Grenoble, France, Université de Grenoble, UMR-S1039, Grenoble, 38000, France,
| | | | | | | | | |
Collapse
|
29
|
Affiliation(s)
- Hans J de Haas
- From the Icahn School of Medicine at Mount Sinai, New York, NY (H.J.d.H., J.N., V.F.); University of Groningen, University Medical Center Groningen, Groningen, The Netherlands (H.J.d.H.); and Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (V.F.)
| | - Jagat Narula
- From the Icahn School of Medicine at Mount Sinai, New York, NY (H.J.d.H., J.N., V.F.); University of Groningen, University Medical Center Groningen, Groningen, The Netherlands (H.J.d.H.); and Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (V.F.)
| | - Valentin Fuster
- From the Icahn School of Medicine at Mount Sinai, New York, NY (H.J.d.H., J.N., V.F.); University of Groningen, University Medical Center Groningen, Groningen, The Netherlands (H.J.d.H.); and Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain (V.F.).
| |
Collapse
|